Heptares Therapeutics

Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, Stabilised Receptors), overcoming a major limiting factor to the development of new drugs targeting this group.
Type
Subsidiary
HQ
Welwyn Garden City, GB
Founded
2007
Heptares Therapeutics was founded in 2007 and is headquartered in Welwyn Garden City, GB

Heptares Therapeutics Office Locations

Heptares Therapeutics has an office in Welwyn Garden City
Welwyn Garden City, GB (HQ)
Broadwater Rd

Heptares Therapeutics Data and Metrics

Heptares Therapeutics Summary

Founding Date

2007

Total Funding

$26 m

Investors

In total, Heptares Therapeutics had raised $26 m

Heptares Therapeutics Financial Metrics

Heptares Therapeutics's revenue was reported to be £5.2 m in FY, 2014
GBPFY, 2014

Revenue

5.2 m

Pre tax profit

(10.9 m)

Net Income

(8.2 m)
GBPFY, 2014

Cash

6.6 m

Accounts Receivable

133.4 k

Current Assets

11.1 m

PP&E

903.6 k

Total Assets

12 m

Accounts Payable

1.2 m

Current Liabilities

2.4 m

Total Liabilities

2.5 m

Retained Earnings

(8.2 m)

Total Equity

9.5 m

Financial Leverage

1.3 x
GBPFY, 2014

Cash From Operating Activities

(11.8 m)

Cash From Financing Activities

9 m

Income Taxes Paid

2.6 m

Heptares Therapeutics Online and Social Media Presence

Heptares Therapeutics Company Life and Culture

You may also be interested in